TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06157151: PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Sponsor: Precigen, Inc · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$1,016,400

Rescue Site Savings

+$693,000

Unlock Full NCT06157151 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06157151 Rescue Dossier →